<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452152</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00047385</org_study_id>
    <secondary_id>9U01HL105198-06</secondary_id>
    <nct_id>NCT01452152</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study</brief_title>
  <acronym>PAPI-2</acronym>
  <official_title>Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is standard treatment to take anti-platelet medication after cardiac catheterization and
      stent placement to help prevent the formation of blood clots that may cause heart attack or
      stroke. The most commonly used anti-platelet medicine is clopidogrel (Plavix®). However,
      researchers have found that people vary in their response to clopidogrel, in part because of
      differences in their genes. Prasugrel (Effient®)is another anti-platelet medication used to
      prevent clots. The genetic differences that affect clopidogrel response do not affect
      prasugrel response. Recently, the FDA added a warning to the label of clopidogrel to notify
      doctors and patients with certain genetic differences may not get the full benefit from
      clopidogrel. Despite this, genetic testing for these variations is not usually done in
      standard medical practice. The purpose of this study is to see if patients with certain gene
      differences have fewer major cardiac events after stent placement if they are given
      anti-platelet therapy guided by their individual genetic type compared to standard
      anti-platelet therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over a three-year period, a total of 7,200 patients undergoing percutaneous coronary
      intervention (PCI) in whom dual anti-platelet therapy is indicated for at least one year and
      meet the eligibility criteria, will be recruited from five or more clinical sites. Patients
      presenting to the cardiac clinics, emergency departments, catheterization laboratories, and
      other acute care units (e.g. CCU) who will have coronary angiography or have had angiography
      and PCI will be offered participation. Following informed consent, patients will have
      baseline data and specimens collected, and eligibility confirmed. Patients will be randomized
      in equal numbers to the G-D arm or SOC arm. Immediately following randomization, a blood
      sample from patients assigned to the G-D arm will be sent for CYP2C19 genotype analysis. Upon
      receipt of CYP2C19 genotype results, patients randomized to the G-D arm with the CYP2C19
      *1/*1 genotype (extensive metabolizers) and *1/*17, and *17/*17 genotypes (ultrarapid
      metabolizers) will receive clopidogrel 75 mg/day plus aspirin 81-162 mg/day (group a). Those
      with *1/*2, *1/*3, *2/*17, and *3/*17 genotypes (intermediate metabolizers) and those with
      *2/*2, *2/*3, and *3/*3 genotypes (poor metabolizers) will receive prasugrel 5-10 mg/day plus
      aspirin 81-162 mg/day (group b). Patients randomized to the SOC arm will not be genotyped
      prospectively. They will receive dual anti-platelet therapy guided by the judgment of their
      treating physician according to standard medical practice irrespective of genotype (group c).
      Optionally, a subgroup of patients will return at 10 days after the randomization visit for
      platelet aggregation studies.

      If our hypothesis is correct, i.e., that in intermediate and poor metabolizers, G-D
      anti-platelet therapy results in fewer cardiovascular events and has less or equivalent
      bleeding complications compared to SOC therapy, and is cost effective, this prospective
      randomized clinical trial will provide the evidence base to implement genotype-directed
      anti-platelet treatment algorithms broadly into clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated by study sponsor.
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Post-randomization Cardiovascular Events</measure>
    <time_frame>One year</time_frame>
    <description>Cardiovascular events include non-fatal myocardial infarction, non-fatal stroke, definite or probable stent thrombosis (ARC definition) and death secondary to any cardiovascular cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Bleeding Events</measure>
    <time_frame>One year</time_frame>
    <description>Bleeding events will classified by the Bleeding Academic Research Consortium definition. The number of bleeding events will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Platelet Aggregation</measure>
    <time_frame>10 days</time_frame>
    <description>Platelet aggregation will be performed on a subset of subjects using VerifyNow P2Y12 which measures platelet reactivity due to the effect of a P2Y12. Values less than 180 P2Y12 Reaction Units (PRU) suggest evidence of a P2Y12 inhibitor effect. Platelet aggregation studies are optional and will not be used to modulate antiplatelet therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Resource Utilization and Cost-effectiveness</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>One year</time_frame>
    <description>The number of subjects reporting any AEs will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of All-cause Death, Myocardial Infarction (MI), Stroke and Repeat Revascularization</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Genotype-directed, clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype-directed, prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
    <arm_group_label>Genotype-directed, clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
    <arm_group_label>Genotype-directed, prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females between the ages of 20 and 74 years, inclusive

          -  Not more than four days post-PCI (percutaneous coronary intervention) with placement
             of one or more drug eluting or bare metal stents

          -  One or more stent(s) delivered with final TIMI 3 flow (thrombolysis in myocardial
             infarction grade 3) in the stented vessel(s)

          -  Must have evidence of one of the following:

               1. Three vessel disease;

               2. Two vessel disease with one of the following: estimated creatinine clearance &lt;60,
                  prior myocardial infarction, diabetes mellitus on treatment, peripheral artery
                  disease, cerebrovascular disease, bifurcation stent, overlapping stents, or total
                  stent deployment length &gt; 40 mm in length;

               3. Single vessel disease with two of the following: estimated creatinine clearance
                  &lt;60, prior myocardial infarction, diabetes mellitus on treatment, peripheral
                  artery disease, cerebrovascular disease, bifurcating stenting, overlapping
                  stents, or total stent deployment length &gt; 40 mm in length.

          -  Patients with acute MI (myocardial infarction) preceding the PCI must have CK-MB
             (bound combination of creatine kinase M and creatine kinase B) value lower than the
             prior value, before randomization

          -  Patients with peri-procedural MI, defined by CK-MB three times greater than upper
             reference limit (URL), must have CK-MB value lower than the prior value, before
             randomization. Peri-procedural MI will be screened per clinical suspicion.

          -  Have an indication for one year of dual anti-platelet therapy with a P2Y12 inhibitor
             and aspirin

          -  Agreement of the treating physician to prescribe anti-platelet therapy according to
             randomization and study dosing algorithm

          -  Ability to understand and comply with planned study procedures

          -  Provide written informed consent prior to study entry

          -  Agrees to authorize the collection and release of his/her medical information for the
             duration of the trial or until the subject withdraws

        Exclusion Criteria:

          -  History of a gastrointestinal bleed within three months or a major, life threatening
             bleeding event (e.g., sub-arachnoid or intracranial hemorrhage)

          -  Active pathological bleeding (e.g. GI bleeding)

          -  History of bleeding diathesis or coagulopathy

          -  History of stroke or transient ischemic attack (TIA)

          -  Non-cardiac surgery within the prior 3 months

          -  Planned cardiac or non-cardiac surgery within the next 12 months

          -  CYP2C19 genotype already known to subject or research team from prior genetic testing

          -  Post-PCI CABG (coronary artery bypass graft) before randomization

          -  Planned warfarin or dabigatran therapy any time during the study period

          -  Known allergy to aspirin, clopidogrel or prasugrel

          -  Platelet count &lt;100,000/mm3

          -  Hematocrit &lt; 25%

          -  Pregnancy

          -  Concurrent enrollment in another trial that involves an investigational stent,
             antithrombotic or anti-platelet agent

          -  Any condition that would, in the opinion of the site investigator, place them at an
             unacceptable risk or render them unable to meet the requirements of the protocol

          -  Any subject, in the opinion of the investigator, not expected to tolerate or be
             adherent with one year of dual antiplatelet therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan R Shuldiner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Center for Thrombosis Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.</citation>
    <PMID>19706858</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>May 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2016</results_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Alan Shuldiner</investigator_full_name>
    <investigator_title>Professor, School of Medicine; Head, Division of Endocrinology, Diabetes and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Genotype-directed, Clopidogrel</title>
          <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
        </group>
        <group group_id="P2">
          <title>Genotype-directed, Prasugrel</title>
          <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
        </group>
        <group group_id="P3">
          <title>Standard of Care</title>
          <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study termination by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotype-directed, Clopidogrel</title>
          <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
        </group>
        <group group_id="B2">
          <title>Genotype-directed, Prasugrel</title>
          <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
        </group>
        <group group_id="B3">
          <title>Standard of Care</title>
          <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Post-randomization Cardiovascular Events</title>
        <description>Cardiovascular events include non-fatal myocardial infarction, non-fatal stroke, definite or probable stent thrombosis (ARC definition) and death secondary to any cardiovascular cause.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype-directed, Clopidogrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O2">
            <title>Genotype-directed, Prasugrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Post-randomization Cardiovascular Events</title>
          <description>Cardiovascular events include non-fatal myocardial infarction, non-fatal stroke, definite or probable stent thrombosis (ARC definition) and death secondary to any cardiovascular cause.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Bleeding Events</title>
        <description>Bleeding events will classified by the Bleeding Academic Research Consortium definition. The number of bleeding events will be tabulated.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype-directed, Clopidogrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O2">
            <title>Genotype-directed, Prasugrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Bleeding Events</title>
          <description>Bleeding events will classified by the Bleeding Academic Research Consortium definition. The number of bleeding events will be tabulated.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Platelet Aggregation</title>
        <description>Platelet aggregation will be performed on a subset of subjects using VerifyNow P2Y12 which measures platelet reactivity due to the effect of a P2Y12. Values less than 180 P2Y12 Reaction Units (PRU) suggest evidence of a P2Y12 inhibitor effect. Platelet aggregation studies are optional and will not be used to modulate antiplatelet therapy.</description>
        <time_frame>10 days</time_frame>
        <population>Optional platelet aggregation was performed in 3 of 5 participants randomized to the Genotype-directed, clopidogrel arm and 0 of 4 participants randomized to the Standard of Care arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype-directed, Clopidogrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O2">
            <title>Genotype-directed, Prasugrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Platelet Aggregation</title>
          <description>Platelet aggregation will be performed on a subset of subjects using VerifyNow P2Y12 which measures platelet reactivity due to the effect of a P2Y12. Values less than 180 P2Y12 Reaction Units (PRU) suggest evidence of a P2Y12 inhibitor effect. Platelet aggregation studies are optional and will not be used to modulate antiplatelet therapy.</description>
          <population>Optional platelet aggregation was performed in 3 of 5 participants randomized to the Genotype-directed, clopidogrel arm and 0 of 4 participants randomized to the Standard of Care arm.</population>
          <units>percentage of inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Care Resource Utilization and Cost-effectiveness</title>
        <time_frame>One year</time_frame>
        <population>This outcome measure has zero total participants analyzed because health care resource utilization and cost-effectiveness data was not collected due to the early termination of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype-directed, Clopidogrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O2">
            <title>Genotype-directed, Prasugrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Care Resource Utilization and Cost-effectiveness</title>
          <population>This outcome measure has zero total participants analyzed because health care resource utilization and cost-effectiveness data was not collected due to the early termination of the trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events</title>
        <description>The number of subjects reporting any AEs will be tabulated.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype-directed, Clopidogrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O2">
            <title>Genotype-directed, Prasugrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events</title>
          <description>The number of subjects reporting any AEs will be tabulated.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of All-cause Death, Myocardial Infarction (MI), Stroke and Repeat Revascularization</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype-directed, Clopidogrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O2">
            <title>Genotype-directed, Prasugrel</title>
            <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of All-cause Death, Myocardial Infarction (MI), Stroke and Repeat Revascularization</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Genotype-directed, Clopidogrel</title>
          <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
clopidogrel: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year</description>
        </group>
        <group group_id="E2">
          <title>Genotype-directed, Prasugrel</title>
          <description>Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
prasugrel: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year</description>
        </group>
        <group group_id="E3">
          <title>Standard of Care</title>
          <description>Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain - cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early by the sponsor due to low enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alan R. Shuldiner</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>410-706-1623</phone>
      <email>ashuldin@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

